Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 6/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903907 | 0.88 | PDE2A (0.36) | CYP3A4CYP2C8PDE2ASCN9ATACR3 | |
| SCHEMBL14119201 | 0.87 | PDE2A (0.33) | CYP3A4CYP2C8PDE2ASCN9ATACR3 | |
| SCHEMBL1907804 | 0.86 | PDE2A (0.34) | CYP3A4CYP2C8PDE2ASCN9ATACR3 | |
| SCHEMBL1904896 | 0.85 | ALDH1A1 (0.41) | MEN1KMT2AKDM4EUSP2ALDH1A1 | |
| SCHEMBL1907255 | 0.84 | SCN9A (0.33) | CYP3A4PDE2ASCN9ATACR3HTR1A | |
| SCHEMBL1902004 | 0.84 | AKT1 (0.43) | — | |
| SCHEMBL1902388 | 0.80 | BRD4 (0.35) | CYP3A4CYP2C8SCN9A | |
| SCHEMBL14119236 | 0.79 | AKT1 (0.40) | CYP3A4PDE2ASCN9ACYP2C9HSD11B1 | |
| SCHEMBL1903477 | 0.79 | TACR3 (0.32) | CYP3A4PDE2ATACR3CYP2C9CYP2C19 | |
| SCHEMBL1902833 | 0.77 | ALDH1A1 (0.39) | KDM4EUSP2ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | CYP3A4 4594/4885CYP2C8 4472/4885PDE2A 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.